1[1]Slamon DJ,Clark GM.Amplification of c-erbB2 and aggressive breast cancer tumors.Science,1988;240:1795～1798
2[2]Ross JS,Yang F,Kallakury BV,et al.HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.Am J Clin Pathol,1999;111(3):311～316
3[3]Mark HF,Feldman D,Das S,et al.Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer.Exp Mol Pathol,1999;66(2):170～178
4[4]Harpole DHJr,Marks JR,Richards WG,et al.Localized adenocarcinoma of the lung:oncogene expression of erbB-2 and p53 in 150 patients.Clin Cancer Res,1995;1(6):659～664
5[5]Yazici H,Altun M,Alatli,et al.c-erbB-2 gene amplification in nasopharyngeal carcinoma.Cancer Invest,2000;18(1):6～10
6[6]Huang MC,Lau YK.Basic science of HER2/neu:A review.Seminars in Oncology,1999;26(4 suppl):51～59
7[7]Slamon DJ,Clark GM,Wong SG,et al.Human breast cancer:correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science,1987;235:177～182
8[8]Karunagaran D,Tzahar E,Beerli RR,et al.ErbB-2 is a common auxiliary subunit of NDF and EGF receptors:implications for breast cancer.EMBO J,1996;15:254～264
9[9]Pinkas-Kramarski R,Soussan L,Waterman H,et al.Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions.EMBO J,1996;15:2452～2467
10[10]Graus-Porta D,Beerli RR,Hynes NE.Single-chain antibody mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling.Mol Cell Biol,1995;15:1182～1191
2Emens LA. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer [J]. Am J Ther, 2005, 12(3): 243-253.
3AGUS DB, BUNN PA JR, FRANKLIN W, et al. HER-2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer[J]. Semin Oncol, 2000, 27(6 Suppl 11): 53-63.
4GREENE FL, COMP TON CC, FRITZ A G, et al. MCC Cancer Staging. Atlas[M]. New York: Springer, 2006: 77-88.
5WOLFF AC, HAMMOND ME, SCHWARTZ JN, et al. American society of clinical oneology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer [J]. J Clin Oncol, 2007, 25(1): 118-145.
6LAUDADIO J, QUIGLEY DI, TUBBS R, et al. HER2 testing: a review of detection methodologies and their clinical performance [J]. Expert Rev Mol Diagn, 2007, 7(1): 53-64.
7DREILICH M, WANDERS A, BRATPSTROM D, et al. HER-2 overexpression (3+) in patients with squamous ceU esophageal carcinoma correlates with poorer survival[J]. Dis Esophagus, 2006, 19(4): 224-231.
8AKAMATSU M, MATSUMOTO T, OKA K. C-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma[J]. Int J Radiat Oncol Biol Phys, 2003, 57(5): 1323-1327.
9SATO S, KAJIYAMA Y, SUGANO M. Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein [J]. Int J Radiat Oncol Biol Phys, 2005, 61(1): 203-211.
10Baselga J,Tripathy D,Mendelsohn J,et al.Phase Ⅱ study of weeklyin travenons trastuzumab(Herceptin)in patients with HER-2/neu overexpressing metastatic breast cancer[J].J Clin Oncol,1996,14(3):737-744.
